A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects

Trial Profile

A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs ACT 451840 (Primary)
  • Indications Malaria
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top